JP2015521593A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521593A5
JP2015521593A5 JP2015516723A JP2015516723A JP2015521593A5 JP 2015521593 A5 JP2015521593 A5 JP 2015521593A5 JP 2015516723 A JP2015516723 A JP 2015516723A JP 2015516723 A JP2015516723 A JP 2015516723A JP 2015521593 A5 JP2015521593 A5 JP 2015521593A5
Authority
JP
Japan
Prior art keywords
seq
aqueous composition
cdr2
cdr3
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516723A
Other languages
English (en)
Japanese (ja)
Other versions
JP6265978B2 (ja
JP2015521593A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/054777 external-priority patent/WO2013186700A1/en
Publication of JP2015521593A publication Critical patent/JP2015521593A/ja
Publication of JP2015521593A5 publication Critical patent/JP2015521593A5/ja
Application granted granted Critical
Publication of JP6265978B2 publication Critical patent/JP6265978B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516723A 2012-06-12 2013-06-11 抗体製剤 Active JP6265978B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261658472P 2012-06-12 2012-06-12
US61/658,472 2012-06-12
PCT/IB2013/054777 WO2013186700A1 (en) 2012-06-12 2013-06-11 Antibody formulation

Publications (3)

Publication Number Publication Date
JP2015521593A JP2015521593A (ja) 2015-07-30
JP2015521593A5 true JP2015521593A5 (enExample) 2016-06-16
JP6265978B2 JP6265978B2 (ja) 2018-01-24

Family

ID=48914378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516723A Active JP6265978B2 (ja) 2012-06-12 2013-06-11 抗体製剤

Country Status (37)

Country Link
US (4) US9216219B2 (enExample)
EP (3) EP2858671B1 (enExample)
JP (1) JP6265978B2 (enExample)
KR (1) KR102124820B1 (enExample)
CN (1) CN104363920B (enExample)
AR (1) AR091413A1 (enExample)
AU (1) AU2013276112B2 (enExample)
BR (1) BR112014030820B1 (enExample)
CA (1) CA2875386C (enExample)
CL (1) CL2014003370A1 (enExample)
CO (1) CO7151487A2 (enExample)
CY (1) CY1122181T1 (enExample)
DK (2) DK2858671T3 (enExample)
EA (1) EA033373B1 (enExample)
EC (1) ECSP15017314A (enExample)
ES (2) ES2751659T3 (enExample)
FI (1) FI3593814T3 (enExample)
GT (1) GT201400285A (enExample)
HR (2) HRP20260513T1 (enExample)
HU (1) HUE045523T2 (enExample)
IL (1) IL235966B (enExample)
LT (2) LT3593814T (enExample)
MA (1) MA37616A1 (enExample)
MX (1) MX363380B (enExample)
MY (1) MY179818A (enExample)
NZ (1) NZ630885A (enExample)
PE (1) PE20150200A1 (enExample)
PH (1) PH12014502778A1 (enExample)
PL (2) PL2858671T3 (enExample)
PT (2) PT3593814T (enExample)
RS (1) RS67957B1 (enExample)
SG (1) SG11201408174UA (enExample)
SI (2) SI2858671T1 (enExample)
TN (1) TN2014000488A1 (enExample)
TW (1) TWI653983B (enExample)
WO (1) WO2013186700A1 (enExample)
ZA (1) ZA201408547B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
LT3060229T (lt) 2013-10-24 2021-09-27 Astrazeneca Ab Stabilios vandeninės antikūno vaistinės formos
CN104730237A (zh) * 2013-12-23 2015-06-24 国家纳米科学中心 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
KR101597037B1 (ko) 2014-06-26 2016-02-24 엘지디스플레이 주식회사 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
CA3290174A1 (en) * 2015-03-30 2026-03-02 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US10994011B2 (en) 2015-12-18 2021-05-04 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human TSLP receptor antibody
EA201892735A1 (ru) * 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
DK3529269T3 (da) 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
WO2018115485A1 (en) 2016-12-22 2018-06-28 Pierfrancesco Tassone A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
TW201834639A (zh) * 2017-03-06 2018-10-01 德商馬克專利公司 水性抗體調配物
BR112019021723A2 (pt) * 2017-04-18 2021-06-29 Dr. Reddy's Laboratories Limited formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
ES2965486T3 (es) * 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
MD3672631T3 (ro) * 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
MA51223A (fr) * 2017-11-29 2020-10-07 Prothena Biosciences Ltd Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
CN113194993A (zh) 2018-12-18 2021-07-30 诺华股份有限公司 含高浓度抗vegf抗体的蛋白质溶液配制品
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
JP2022521624A (ja) * 2019-02-26 2022-04-11 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 抗ｃｄ４７抗体を含む製剤、その調製方法および使用
CA3160207A1 (en) 2019-11-06 2021-05-14 Novartis Ag Treatment for sjogren's syndrome
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
CN115052622B (zh) * 2020-01-21 2026-03-06 夏尔巴生物技术(杭州)有限公司 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
JP7834711B2 (ja) * 2020-08-04 2026-03-24 ノバルティス アーゲー Ｂ細胞悪性腫瘍の治療
IL300087A (en) * 2020-08-04 2023-03-01 Novartis Ag Treatment of CLL
JP2023553641A (ja) * 2020-12-17 2023-12-25 アストラゼネカ アクチボラグ 抗ｉｌ５ｒ抗体製剤
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
US20240228644A1 (en) * 2021-05-04 2024-07-11 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
US20240239911A1 (en) 2021-05-04 2024-07-18 Novartis Ag Treatment for lupus nephritis using anti-baffr antibodies
JP2024537772A (ja) * 2021-09-29 2024-10-16 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｂａｆｆ－ｒを標的化する抗体及びその使用
EP4615502A1 (en) 2022-11-07 2025-09-17 Upstream Bio, Inc. Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
CN118681009A (zh) * 2023-03-21 2024-09-24 百奥泰生物制药股份有限公司 一种复方制剂及其应用
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法
WO2025257781A1 (en) * 2024-06-14 2025-12-18 Novartis Ag Treatment of systemic sclerosis using anti-baff-r antibodies
WO2025263459A1 (ja) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 バイオ医薬品組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2000078930A1 (en) 1999-06-23 2000-12-28 Oregon Health Sciences University Method for enhancing hematopoiesis
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0518994A2 (pt) * 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
AU2009272771B2 (en) * 2008-07-17 2012-09-20 Novartis Ag Compositions and methods of use for therapeutic antibodies
RU2558821C2 (ru) * 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation

Similar Documents

Publication Publication Date Title
AR091413A1 (es) Formulacion de anticuerpos
JP2013543505A5 (enExample)
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
AR124140A2 (es) Formulaciones de anticuerpos
HRP20191199T1 (hr) Formulacije protutijela anti-prolaktinskog receptora
JP2017031213A5 (enExample)
JP2015519382A5 (enExample)
NZ730821A (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
AR095451A1 (es) Formulación de anticuerpos
JP2013517277A5 (enExample)
RU2015119547A (ru) Стабильный низковязкий состав с антителом
JP2012136541A5 (enExample)
JP2015007098A5 (enExample)
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
JP2016539921A5 (enExample)
HRP20191137T1 (hr) Formulacije otopina konstruiranih anti-il-23p19 antitijela
AR077225A1 (es) Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
JP2019501920A5 (enExample)
RU2015134422A (ru) Применение левоцитиризина и монтелукаста при лечении васкулита
JP2016505572A5 (enExample)
EP4506016A3 (en) Pharmaceutical composition containing anti-human tslp receptor antibody
JP2015513535A5 (enExample)
JP2016512247A5 (enExample)
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf